Co-sleeping mothers at higher risk of developing depression, new study claims

Agencies
March 2, 2018

Washington, Mar 2: Turns out, mothers who co-sleep with infants beyond six months may feel more depressed and judged by others.

According to a Penn State-study, mothers who choose to co-sleep with their infants are more likely to feel depressed or judged when faced with recent trends and popular advice telling moms not to sleep with their babies.

After analyzing moms' sleeping patterns and feelings about sleep for the first year of their babies' lives, the researchers found that mothers who were still co-sleeping - sharing either a room or bed - with their infants after six months were more likely to feel depressed, worried about their babies' sleep and think their decisions were being criticized.

Douglas Teti of the Penn State said that regardless of current parenting trends, it's important to find a sleep arrangement that works for everyone in the family.

"In other parts of the world, co-sleeping is considered normal, while here in the U.S., it tends to be frowned upon," Teti said. "Co-sleeping, as long as it is done safely, is fine as long as both parents are on board with it. If it's working for everyone, and everyone is okay with it, then co-sleeping is a perfectly acceptable option."

The researchers said that while most American families begin co-sleeping when their babies are first born, most of those families transition the babies to their own room by the time he or she is six months old. Teti said concerns about sudden infant death syndrome (SIDS) or the desire for babies to learn how to fall asleep on their own may be why many parents in the U.S. prefer their babies to be sleep alone.

Teti said this study - which analysed the sleeping habits of 103 mothers in their baby's first year of life - saw a similar pattern in its participants. "We found that about 73 percent of families co-slept at the one-month point. That dropped to about 50 percent by three months, and by six months, it was down to about 25 percent," Teti said. "Most babies that were in co-sleeping arrangements in the beginning were moved out into solitary sleep by six months."

On average, mothers that were still co-sleeping after six months reported feeling about 76 percent more depressed than mothers who had moved their baby into a separate room. They also reportedly felt about 16 percent more criticised or judged for their sleep habits.

"We definitely saw that the persistent co-sleepers -- the moms that were still co-sleeping after six months -- were the ones who seemed to get the most criticism," Teti said. "Additionally, they also reported greater levels of worry about their baby's sleep, which makes sense when you're getting criticized about something that people are saying you shouldn't be doing, that raises self-doubt. That's not good for anyone."

Teti said that the study isn't about whether co-sleeping is good or bad, but about the importance of finding a sleep arrangement that works well while not neglecting your partner or spouse.

"If you're going to co-sleep, you have to make sure both people in the partnership have talked it through and both people are in sync with what they want to do," Teti said. "If not, that's when criticism and arguments can happen and possibly spill over into the relationship with child. So you want to avoid that. You need to make sure you have time with your partner, as well."

Teti also said that even when co-sleeping works well, it can still cause more loss of sleep for the parents than if the baby slept in its own room.

"If you co-sleep, it is going to disrupt your sleep, and probably Mom's sleep more than Dad's," Teti said. "So this is something to be careful with if you're not good with chronic sleep debt. Co-sleeping needs to work well for everyone, and that includes getting adequate sleep. To be the best parent you can be, you have to take care of yourself, and your child benefits as a result", concluded Teti.

The study is published in the journal Infant and Child Development.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
June 20,2020

The World Health Organisation has warned that the COVID-19 pandemic is entering a "new and dangerous" phase. Thursday saw the most cases in a single day reported to the WHO.

Tedros Adhanom Ghebreyesus said the day had seen 150,000 new cases with half of those coming from the Americas and large numbers also from the Middle East and South Asia, the BBC reported.

He said the virus was still spreading fast and the pandemic accelerating.

He acknowledged people might be fed up with self-isolating and countries were eager to open their economies but he said that now was a time for extreme vigilance.

Maria van Kerkhove, technical lead of the WHO's COVID-19 response, told a press conference the pandemic is "accelerating in many parts of the world".

"While we have seen countries have some success in suppressing transmission and bringing transition down to a low level, every country must remain ready," she said.

Mike Ryan, the head of the WHO's Health Emergencies Programme, said that some countries had managed to flatten the peak of infections without bringing them down to a very low level.

"You can see a situation in some countries where they could get a second peak now, because the disease has not been brought under control," he said.

"The disease will then go away and reduce to a low level, and they could then get a second wave again in the autumn or later in the year."

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
February 26,2020

New York, Feb 26:  A new wearable sensor that works in conjunction with artificial intelligence (AI) technology could help doctors remotely detect critical changes in heart failure patients days before a health crisis occurs, says a study.

The researchers said the system could eventually help avert up to one in three heart failure readmissions in the weeks following initial discharge from the hospital and help patients sustain a better quality of life.

"This study shows that we can accurately predict the likelihood of hospitalisation for heart failure deterioration well before doctors and patients know that something is wrong," says the study's lead author Josef Stehlik from University of Utah in the US.

"Being able to readily detect changes in the heart sufficiently early will allow physicians to initiate prompt interventions that could prevent rehospitalisation and stave off worsening heart failure," Stehlik added.

According to the researchers, even if patients survive, they have poor functional capacity, poor exercise tolerance and low quality of life after hospitalisations.

"This patch, this new diagnostic tool, could potentially help us prevent hospitalizations and decline in patient status," Stehlik said.

For the findings, published in the journal Circulation: Heart Failure, the researchers followed 100 heart failure patients, average age 68, who were diagnosed and treated at four veterans administration (VA) hospitals in Utah, Texas, California, and Florida.

After discharge, participants wore an adhesive sensor patch on their chests 24 hours a day for up to three months.

The sensor monitored continuous electrocardiogram (ECG) and motion of each subject.

This information was transmitted from the sensor via Bluetooth to a smartphone and then passed on to an analytics platform, developed by PhysIQ, on a secure server, which derived heart rate, heart rhythm, respiratory rate, walking, sleep, body posture and other normal activities.

Using artificial intelligence, the analytics established a normal baseline for each patient. When the data deviated from normal, the platform generated an indication that the patient's heart failure was getting worse.

Overall, the system accurately predicted the impending need for hospitalization more than 80 per cent of the time.

On average, this prediction occurred 10.4 days before a readmission took place (median 6.5 days), the study said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
May 26,2020

Tedros Adhanom Ghebreyesus, the World Health Organisation's (WHO) Director-General, said that a clinical trial of hydroxychloroquine (HCQ) on COVID-19 patients has come to "a temporary pause", while the safety data of the the anti-malaria drug was being reviewed.

According to the WHO chief, The Lancet medical journal on May 22 had published an observational study on HCQ and chloroquine and its effects on COVID-19 patients that have been hospitalized, reports Xinhua news agency.

The authors of the study reported that among patients receiving the drug, when used alone or with a macrolide, they estimated a higher mortality rate.

"The Executive Group of the Solidarity Trial, representing 10 of the participating countries, met on Saturday (May 23) and has agreed to review a comprehensive analysis and critical appraisal of all evidence available globally," Tedros said in a virtual press conference on Monday.

The review will consider data collected so far in the Solidarity Trial and in particular robust randomized available data, to adequately evaluate the potential benefits and harms from this drug, he said.

"The Executive Group has implemented a temporary pause of the HCQ arm within the Solidarity Trial while the safety data is reviewed by the Data Safety Monitoring Board. The other arms of the trial are continuing," Tedros added.

WHO initiated the Solidarity Trial, a plan to evaluate the safety and efficacy of four drugs and drug combinations against COVID-19 more than two months ago, which include HCQ.

According to the WHO, over 400 hospitals in 35 countries are actively recruiting patients and nearly 3,500 patients have been enrolled from 17 countries under the Solidarity Trial.

Tedros added that the safety concern over the drug related only to the use of HCQ and chloroquine in COVID-19, and "these drugs are accepted as generally safe for use in patients with autoimmune diseases or malaria".

"WHO will provide further updates as we know more," he added.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.